Breaking News Instant updates and real-time market news.

VRX

Ticker changed BHC

$15.37

0.235 (1.55%)

07:10
08/08/17
08/08
07:10
08/08/17
07:10

Valeant sees exceeding commitment to pay down $5B in debt before Feb. 2018

Along with its quarterly report, Valeant said it has reduced total debt by more than $4.8B since the end of the first quarter of 2016. Valeant noted it has no debt maturities and no mandatory amortization requirements until 2020. Valeant also said it expects to exceed its commitment to pay down $5B in debt from divestiture proceeds and free cash flow before February 2018.

  • 08

    Aug

  • 24

    Aug

VRX Ticker changed BHC
$15.37

0.235 (1.55%)

07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
09/19/18
09/19
11:16
09/19/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,911.33

-29.87 (-1.54%)

11:14
09/19/18
09/19
11:14
09/19/18
11:14
Periodicals
EU antitrust regulator looking at Amazon's use of merchant data, Reuters reports »

The EU's competition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAO

Nordic American Offshore

$0.94

-0.015 (-1.58%)

11:11
09/19/18
09/19
11:11
09/19/18
11:11
Hot Stocks
Nordic American Offshore announces receipt of notice from NYSE »

Nordic American Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$40.68

0.37 (0.92%)

11:00
09/19/18
09/19
11:00
09/19/18
11:00
Options
Repeat put buying in Chemours Company »

Repeat put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$84.55

-0.48 (-0.56%)

, TCEHY

Tencent

$0.00

(0.00%)

10:59
09/19/18
09/19
10:59
09/19/18
10:59
Periodicals
Novartis, Tencent to partner, focus on cardiovascular disease, Bloomberg says »

Bloomberg cites an email…

NVS

Novartis

$84.55

-0.48 (-0.56%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

UNP

Union Pacific

$162.66

-1.04 (-0.64%)

10:58
09/19/18
09/19
10:58
09/19/18
10:58
Recommendations
Union Pacific analyst commentary  »

Union Pacific call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 06

    Nov

PDD

Pinduoduo

$23.56

0.92 (4.06%)

10:55
09/19/18
09/19
10:55
09/19/18
10:55
Options
Pinduoduo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:50
09/19/18
09/19
10:50
09/19/18
10:50
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

10:45
09/19/18
09/19
10:45
09/19/18
10:45
General news
El-Erian hinting at further yield rise implications »

El-Erian hinting at…

10:45
09/19/18
09/19
10:45
09/19/18
10:45
Hot Stocks
Breaking Hot Stocks news story  »

SilverCrest Metals Inc…

10:40
09/19/18
09/19
10:40
09/19/18
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

AN

AutoNation

$44.15

1.06 (2.46%)

, GM

General Motors

$35.69

0.58 (1.65%)

10:38
09/19/18
09/19
10:38
09/19/18
10:38
Hot Stocks
AutoNation CEO Jackson to step down in 2019 after nearly 20 years »

Shares of AutoNation (AN)…

AN

AutoNation

$44.15

1.06 (2.46%)

GM

General Motors

$35.69

0.58 (1.65%)

F

Ford

$9.79

0.205 (2.14%)

BRK.A

Berkshire Hathaway

$329,890.01

2310.01 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GS

Goldman Sachs

$232.76

3.81 (1.66%)

, JPM

JPMorgan

$116.50

2.15 (1.88%)

10:37
09/19/18
09/19
10:37
09/19/18
10:37
Periodicals
Goldman nearing deal to spin off fintech app 'Simon,' WSJ reports »

Goldman Sachs (GS) is in…

GS

Goldman Sachs

$232.76

3.81 (1.66%)

JPM

JPMorgan

$116.50

2.15 (1.88%)

HSBC

HSBC

$44.01

0.72 (1.66%)

BCS

Barclays

$9.26

0.155 (1.70%)

WFC

Wells Fargo

$55.06

0.555 (1.02%)

CS

Credit Suisse

$15.30

0.21 (1.39%)

PRU

Prudential

$102.38

2.16 (2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 21

    Oct

  • 26

    Feb

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

MRVL

Marvell

$18.60

-0.06 (-0.32%)

10:37
09/19/18
09/19
10:37
09/19/18
10:37
Conference/Events
Marvell management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

10:37
09/19/18
09/19
10:37
09/19/18
10:37
Conference/Events
Morgan Stanley multi-industrial analysts hold analyst/industry conference call »

U.S. Electrical Equipment…

INO

Inovio

$4.87

0.01 (0.21%)

10:36
09/19/18
09/19
10:36
09/19/18
10:36
Conference/Events
Inovio management to meet with Piper Jaffray »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

XYF

X Financial

$0.00

(0.00%)

10:36
09/19/18
09/19
10:36
09/19/18
10:36
Syndicate
Breaking Syndicate news story on X Financial »

X Financial opens at $15,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

10:35
09/19/18
09/19
10:35
09/19/18
10:35
General news
Crude inventories for week of September 14 »

Crude oil inventories…

SPY

SPDR S&P 500 ETF Trust

$290.95

-0.01 (-0.00%)

, SPX

S&P 500

$0.00

(0.00%)

10:32
09/19/18
09/19
10:32
09/19/18
10:32
General news
New NAFTA deal with Canada unlikely to be reached this week, Bloomberg says »

A new NAFTA deal between…

SPY

SPDR S&P 500 ETF Trust

$290.95

-0.01 (-0.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$5.86

0.06 (1.03%)

, HUM

Humana

$336.41

0.57 (0.17%)

10:31
09/19/18
09/19
10:31
09/19/18
10:31
Hot Stocks
Fitbit in focus amid expanded strategic partnership with Humana »

Shares of smartband and…

FIT

Fitbit

$5.86

0.06 (1.03%)

HUM

Humana

$336.41

0.57 (0.17%)

AAPL

Apple

$215.54

-2.7 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

WMT

Walmart

$95.72

0.29 (0.30%)

, JSAIY

J Sainsbury

$0.00

(0.00%)

10:30
09/19/18
09/19
10:30
09/19/18
10:30
Hot Stocks
U.K. regulator refers Sainsbury acquisition of Asda for in-depth investigation »

In August, the…

WMT

Walmart

$95.72

0.29 (0.30%)

JSAIY

J Sainsbury

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 15

    Nov

  • 03

    Mar

FIT

Fitbit

$5.87

0.07 (1.21%)

, HUM

Humana

$336.41

0.57 (0.17%)

10:29
09/19/18
09/19
10:29
09/19/18
10:29
Recommendations
Fitbit, Humana analyst commentary  »

Fitbit launch of…

FIT

Fitbit

$5.87

0.07 (1.21%)

HUM

Humana

$336.41

0.57 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

FISI

Financial Institutions

$32.15

-0.15 (-0.46%)

10:29
09/19/18
09/19
10:29
09/19/18
10:29
Conference/Events
Financial Institutions management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

EVER

EverQuote

$15.04

0.15 (1.01%)

10:27
09/19/18
09/19
10:27
09/19/18
10:27
Conference/Events
EverQuote management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

DY

Dycom

$84.52

1.04 (1.25%)

10:26
09/19/18
09/19
10:26
09/19/18
10:26
Conference/Events
Dycom management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.